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Entrapment of anti-DNA antibodies in the kidney of patients
with systemic lupus erythematosus
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The Third Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Hongo, Tokyo, Japan
Entrapment of anti-DNA antibodies in the kidney of patients with
systemic lupus erythematosus. Antibodies to single-stranded DNA (anti-
ssDNA) and double-stranded DNA (anti-dsDNA) were determined in
serum and urine of nine patients with systemic lupus erythematosus
(SLE) presenting with heavy proteinuria (>300 mg/dl), and the activity
of anti-DNA antibodies was compared between paired serum and urine
samples in each patient. The results were expressed by the anti-DNA
activity (radioimmunoassay units per milliliter) divided by the concen-
tration of IgG (milligrams per milliliter), so as to correct for the
difference of IgG concentration. Anti-DNA was detected invariably in
the serum of these patients (anti-ssDNA/IgG 4.8 to 27.2, anti-dsDNA
5.6 to 107.8). In contrast, anti-DNA activity was not detectable in urine
samples from any of the nine patients. The urine samples from these
patients, as well as those from normal individuals, were found to
contain ssDNA at levels not significantly different from each other (0.25
0.15 vs. 0.19 0.07 pgImg creatinine, P >0.1). The failure to detect
anti-DNA in the urine of SLE patients, however, was not due to the
ssDNA contained in the urine, because no anti-DNA activity was
detected even after their urine samples had been digested with deoxyri-
bonuclease. On the basis of these results, anti-DNA in the serum of
SLE patients was considered to be entrapped in the kidney, probably
owing to its binding with DNA deposited in their glomeruli.
Sequestration des anticorps anti-DNA dans les reins de malades ayant
un lupus erythemateux dissemine. Les anticorps diriges contre du DNA
a simple brin (anti-ssDNA) et a double brin (anti-dsDNA) ont été
mesurés dans le serum et les urines de neuf malades ayant un lupus
érythemateux disséminé (SLE) avec une proteinurie abondante (>300
mg/dl) et l'activité des anticorps anti-DNA a été comparde entre des
echantillons appariés de serums et d'urines chez chaque malade. Les
résultats sont expnmés par l'activité anti-DNA (unite de radio-
immunoassay par millilitre) divisde par la concentration d'IgG (milli-
grammes par millilitre), afin de corriger la difference en concentration
d'IgG. Les anti-DNA étaient invariablement trouvés dans les serums de
ces malades (anti-ssDNAIIgG 4,8 a 27,2, anti-dsDNA 5,6 a 107,8). En
revanche, l'activité anti-DNA n'était pas detectable dans les urines
d'aucun de ces neufmalades. Les échantillons urinaires de ces malades,
comme ceux d'individus normaux, contenaient du ssDNA a une
concentration non significativement différente l'une de l'autre (0,25
0,15 contre 0,19 0,07 pg/mg de créatinine, P> 0,1). L'impossibilité
de détecter les anti-DNA dans l'urine des malades avec an SLE n'était
cependant pas due au ssDNA contenu dans l'urine, puisqu'aucune
activité anti-DNA n'a ete ddtectée, méme après que les échantillons
urinaires aient été digeres avec de la desoxyribonuclease. Sur Ia base de
ces résultats, les anti-DNA du serum des malades ayant un SLE ant été
considérés séquestres dans le rein, probablement en raison de leur
liaison au DNA depose dans leurs glomérules.
also as an indicator of the disease activity. Levels of anti-DNA
antibodies have been reported to correlate with clinical activity
and also with renal involvement 11—71. However, there are
patients in whom the anti-DNA titer may start to decrease as
they develop heavy proteinuria and the nephrotic syndrome 181.
Indeed, anti-DNA antibodies in these patients sometimes de-
crease to a level too low to be detected by the fluorescent
antibody technique. A possible explanation would be that anti-
DNA antibodies are excreted into the urine to lower the serum
level of anti-DNA antibodies. This view, however, does not
conform to the presence of IgG, albeit at low concentrations, in
the serum of nephrotic patients whose anti-DNA activity be-
came undetectable. Anti-DNA antibodies have to be deprived
specifically from the circulation.
Since the kidney is affected preferentially in SLE patients,
possibly by a DNA-anti-DNA immune complex mechanism, it
would be responsible, at least partly, for the decreased levels of
anti-DNA in their sera. In this investigation, we determined the
ratio of anti-DNA antibody titer to the IgG content in the urine,
and compared it with that in the corresponding serum of nine
patients with massive proteinuria to see if anti-DNA in the
serum would be absorbed by the kidney during glomerular
filtration.
Methods
Patients. Of 50 patients (3 male, 47 female, aged 21 to 53
years) who had SLE and had been attending the outpatient
clinic of the Third Department of Internal Medicine of Tokyo
University Hospital, 17 presented with abnormal proteinuria.
Thirteen of the 17 patients had persistent proteinuria exceeding
300 mg/dl. Serum and urine samples were available in adequate
quantity and condition for examination from only nine of them
(Table 1). All 9 patients had received renal biopsy; eight were
diagnosed as having membranous glomerulonephritis and the
remaining one was said to have diffuse proliferative glomerulo-
nephritis. All of them were on 5 to 20 mg of prednisolone daily
at the time of the study. Urine samples were collected on the
same day when blood samples were drawn. Immediately after
Antibodies to double-stranded DNA (anti-dsDNA) and sin-
gle-stranded DNA (anti-s5DNA) are almost always present in
the serum of patients with systemic lupus erythematosus (SLE)
and have been applied as a useful marker for the diagnosis and
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Table 1. Renal involvement and clinical status of SLE patients
Patient Age
no. years
1 47
2 32
3 38
4 38
5 52
6 20
7 38
8 41 F
9 18 F
Serum protein
Albumin
mgld/
2.9
3.8
3.6
2.8
3.6
3.4
3.5
6.0 3.0
6.5 2.8
Urinary
protein Pathology
,ng'dI in the kidney
1000 Membranous
300 Membranous
370 Membranous
660 Membranous
510 Membranous
450 Diffuse proliferative
310 Membranous
370 Membranous
390 Membranous
voiding, they were centrifuged at >< I ,000g for 10 mm and
concentrated to 1/50 to 1/100 of the original volume by negative
pressure ultrafiltration, and dialyzed against Tris-HCI buffer
(0.02 M, pH 7.8) containing 0.13 M NaCI (hereafter referred to
as Tris buffer). Paired serum and urine samples were stored at
—20° C until used. On the day of assay, they were thawed and
heated at 56° C for 30 mm.
Radio/abe/ed DNA reagents. ss-DNA was labeled with 1251
alter the method originally described by Commerford [9]. Calf
thymus DNA (type 1, Sigma Chemical Co., St. Louis, Missouri)
was dissolved in physiological saline at 500 tg/ml and dena-
tured by heating at 100° C for 10 mm followed by immediate
cooling in an ice bath. Mixture of 0.1 ml ssDNA solution (500
g/ml), 0.1 ml 1.25 X i04 M KI, 0.5 mCi Na'251 (New England
Nuclear, Boston, Massachusetts) and 0.1 ml 7.5 >< 10 '
thallium chloride (Soekawa Chemicals, Tokyo, Japan) was
heated at 60° C for 60 mm. After being cooled in an ice bath, the
reaction mixture was applied to a column of Sephadex G-50
(Pharmacia Fine Chemicals, Uppsala, Sweden) equilibrated
with Tris buffer for the separation of bound from free iodine.
When void volume fractions were collected and subjected to gel
filtration in Bio-Gel A-l.5 m (Bio Rad Laboratories, Richmond,
California), a high peak of radioactivity appeared at break-
through fractions, but some radioactivity was detected also in
retarded fractions. Only void volume fractions were collected
and used as 1251-ssDNA (specific activity 2,4 tCi/g). After the
gel filtration on Bio-Gel A-l.5 m, the total binding of 125j
ssDNA with an excess amount of anti-DNA increased from 73
to 91%.
'25IdsDNA was obtained from a commercial source (Amer-
sham, Buckingham shire, England).
Anti-DNA antibodies. Five microliters of serum or concen-
trated urine sample were diluted with Tris buffer to 50 J and
mixed with 10 .d of Tris buffer containing 2 ng of '251-ssDNA
(or 25 .d of 1251-dsDNA solution) in a glass tube measuring 12 x
75 mm. Tubes were incubated for 1 hr at 37° C and for 18 hr at
4° C. Then, 50 d of rabbit antiserum containing anti-human IgG
antibodies were added. After 30 mm of incubation at room
temperature, the formed precipitate was washed twice by
centrifuging xl,000g for 10 mm. The radioactivity in the
precipitate was counted by a gammacounter. The results were
expressed as the number of radioimmunoassay (RIA) units
contained in 1 ml of the sample. One RIA unit was defined as
the amount of anti-DNA which could bind with 50% of the
added radioactivity. Usually, two or more points of twofold
dilutions of the sample were assayed so as to contain 50%
binding between two points.
Radioimmunoassay of human IgG. The concentration of IgG
in serum and urine was determined by radioimmunoassay.
Human IgG (HGG, Miles Laboratories Inc., Elkhart, Indiana)
was labeled with 125j b chloramin T method [101 and '251-HGG
with a specific activity of 2.5 Ci/rg was obtained. Serum and
concentrated urine samples were diluted appropriately with
Tris buffer and a portion (5 to SO l) was delivered to a glass
tube. The total volume was adjusted to 50 /Ll with the buffer.
Ten microliters of Tris buffer containing 0.005 d rabbit anti-
human IgG/y antiserum (Sigma Chemical Co., St. Louis, Mis-
souri) and 1 d of normal rabbit serum were delivered to each
tube, and after a disequilibrium time of 2 hr at 24° C, 10 ng of
'25IHGG in 10 tl of Tris buffer were added. After a further
incubation for 2 hr at 24° C and 18 hr at 4° C, 15 l of goat anti-
rabbit IgG antiserum were added. Tubes were allowed to stand
for 30 mm at 24° C. The formed precipitate was washed twice
and the radioactivity was counted. Using serial dilution of the
standard HGG, an inhibition curve was drawn. igG concentra-
tion in the test sample was determined by comparing its
inhibition with the standard inhibition curve.
Radioimmunoassay of ssDNA. Radioimmunoassay of
ssDNA was performed using anti-ssDNA antibody raised in
rabbits. Five-hundred micrograms of denatured calf thymus
DNA (type 1) dissolved in 1 ml of saline were complexed to 50
l of 1% methylated bovine serum albumin (Sigma Chemical
Co., St. Louis, Missouri), and emulsified in the same volume of
Freund's complete adjuvant (Difco Laboratories, Detroit,
Michigan). Each rabbit received 2.0 ml of the emulsion in hind
footpads and intracutaneously four times at a week interval.
One week after the last injection, blood was drawn and the
serum was separated.
Urine samples were diluted with Tris buffer to the final
volume of 50 1 in a glass tube and incubated with 10 1 of Tris
buffer containing 0.005 l of rabbit anti-DNA antiserum and 1
.d of normal rabbit serum at 24° C for 2 hr. Then 4 ng of 125j
ssDNA in 10 pJ of Tris buffer were added to each tube. After an
incubation for 2 hr at 24° C and then for 18 hr at 4° C, 15 /Ll of
goat anti-rabbit IgG antiserum (Miles Laboratories Inc., Elk-
hart, indiana) were added. Tubes were allowed to stand for 30
mm at 24° C. The formed precipitate was washed twice by
centrifuging at xl,000g for 10 mm, and the radioactivity was
Sex
M
F
F
Duration of
the disease
years
13
8
17
Total protein
nlg/d!
5.3
6.5
6.5
F 11 5.7
F 9 6.8
F 3 6.1
F 17
24
2
6.5
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Fig. 1. Gelfilt ration of the serum from a SLE patient. One-half milliliter
of serum was chromatographed on a Sephacryl S-200 column (12 x 440
mm, bed volume 50 ml) and 0.5-ml fractions were collected. A 50-pi
portion of each fraction was mixed with 10 bd of Tris buffer containing 2
ng '251-ssDNA. After an incubation for 1 hr at 37°C and 18 h at 4°C, 60
d of saturated (NH4)2S04 solution were added. Tubes were centrifuged
at x I ,000g for 10 mm and the radioactivity in the precipitate was
counted. Anti-ssDNA activity was expressed as radioimmunoassay
units per milliliter (see Methods). Open circles and the solid line
represent anti-ssDNA activity; the dotted line represents the absor-
bance at 280 nm. Almost all of the anti-ssDNA activity appeared in IgG
fractions.
counted. Using a serial dilution of ssDNA, the standard curve
was drawn. ssDNA in the test sample was determined by
comparing its inhibition with the standard curve.
Deoxyribonuclease digestion. Digestion of DNA by deoxyri-
bonuclease (DNase) was carried out with a slight modification
of the method originally described by Harbeck et al [11]. Forty-
five microliters of serum or concentrated urine sample were
mixed with 5 tg of DNase I (Sigma Chemical Co., St. Louis,
Missouri) dissolved inS tl of phosphate buffer (0.02 M, pH 7.4)
containing 0.13 M NaCI (phosphate-buffered saline, PBS) in the
presence of 0.15 mole MgCl2. In the control (undigested)
sample, DNase was substituted by PBS. Samples were incubat-
ed at 37° C for 1 hr followed by an overnight incubation at 4° C
and then 2 hr at 24° C. Five microliters of 0.5 M tetrasodium
ethylene diamine tetraaceteic acid (EDTA) dissolved in distilled
water were added to samples to stop the digestion. To achieve a
final serum dilution of 1:10, 395 t1 of borate buffer (0.01 M, pH
8.3) were added to the sample. To the undigested control, 395 d
of borate buffer containing 5 g of DNase I and 0.15 prnole of
MgCl2 were added. A 200-pd portion was taken from each
sample and the activity to bind with DNA was determined by
radioimmunoassay.
Determination of anti-nuclear factors. Determination of anti-
nuclear factors (AN F) was carried out according to the method
described by Beck [12].
Results
Predominance of anti-DNA antibodies of IgG class in the
serum of SLE patients. Serum samples from SLE patients were
chromatographed on a column of Sephacryl S-200 (Pharmacia
Fine Chemicals, Uppsala, Sweden) equilibrated with Tris buff-
E
0 The pattern of a representative serum (patient no. 6) isg illustrated in Figure 1. Anti-DNA activity was detected almost
exclusively in fractions containing IgG. The other serum con-
! centrations showed similar patterns of anti-DNA activity.3.0 Based on these results, following anti-DNA assays were per-
< formed by the double antibody method using rabbit antiserum
to human IgG as a second antibody.
1.0 Comparison of anti-DNA activity in the serum and urine
samples of patients with proteinuria. Anti-DNA was deter-
mined in the nine patients with proteinuria (>300 mg/dl) listed
in Table 1. Anti-DNA activity in the urine was compared with
that in the serum by means of the following index.
Anti-DNA activity (RIA U/mi)
IgG content (mg/mi)
The results are summarized in Table 2. All of these serum
concentrations were positive for anti-ssDNA (range, 42 to 450,
mean 219 RIA U/ml), as well as for anti-dsDNA (range, 58 to
1,250, mean 251 RIA U/mi). Anti-ssDNA and -dsDNA activities
were not detectable in concentrated urine samples from all
these patients (less than 1). Consequently, the indices of urine
samples were extremely low (less than 1.0) contrasting with
those of the corresponding serum samples which measured 4.8
to 27.2 for anti-ssDNA and 5.6 to 107.8 for anti-dsDNA. These
results indicated that although IgG molecules (which accounted
for the majority of anti-DNA activity in the serum, see above)
were excreted in substantial amounts into the urine of these
patients, the amount of anti-DNA in the urine was very little.
ANF in various patterns was detected in serum and concentrat-
ed urine in some of the patients with a titer roughly in parallel
with the concentration of IgG.
The low indices of SLE patients were not due to the
overestimation of urinary IgG by small degradates of IgG
bearing its antigenicity but devoid of antibody activity, such as
Fc and Fe' fragments. Figure 2 shows the profile of IgG activity
in the urine fractionated through a Sephacryl S-200 column.
Essentially all the IgG detectable by radioimmunoassay ap-
peared at the position of intact IgG molecules, thereby indicat-
ing that the contribution of fragments of IgG to the assay would
be little, if any.
Excretion of DNA into the urine of SLE patients. Although
the ratio of anti-DNA antibody titer to the IgG content in the
urine of SLE patients with proteinuria was found to be much
lower than that in the corresponding serum, anti-DNA in the
glomerular filtrate, if present, could have been consumed
during its passage through the urinary tract. To evaluate this
possibility, we tested for the presence of ssDNA in the urine of
SLE patients and normal controls.
When urine samples of patients were concentrated and tested
by radioimmunoassay, all of them were found to contain
ssDNA. Figure 3 shows the inhibition curve of urine from a
representative patient.
The amount of ssDNA excreted was standardized on the
basis of creatinine to correct for the concentration of urine.
ssDNA (ig)/creatinine (mg) in the urine from 28 SLE patients
300
200
2C
100
er. A 50-pi portion of each fraction was tested for anti-ssDNA
by radioimmunoassay, in which (NH4)2S04 was used for pre-
cipitating radioactive DNA bound with antibodies of all classes
[13].
30 40 50 60
Fraction number
Index =
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Table 2. Anti-DNA antibodies and anti-nuclear factors in serum and urine of SLE patients
Anti-nuclear
Patient
no.
Anti-ssD
RIA, U
Serum
NA
/m1'
Urineb
Anti-
RIA
Serum
dsDNA
, U/mi
--
Urine
factors"
Titer and pattern
Serum Urine
IgG
mg/mi
Serum Urine
Anti-ssDNA/IgG
Serum Urine
Anti-dsDNA/IgG
Serum Urine
1 132 <1 58 <1 (—) (—) 8.0 3.6 16.5 <1.0 7.3 <1.0
2 357 <1 128 <1 160 s 40 s 13.4 3.6 26.6 <1.0 9.6 <1.0
3 285 <1 192 <1 40s Is 13.4 10.5 21.3 <1.0 14.3 <1.0
4 42 <1 63 <1 (—) (—) 8.8 3.1 4.8 <1.0 7.2 <1.0
5 161 <1 270 <1 40 h I h 12.8 2.1 12.6 <1.0 21.1 <1.0
6 227 <1 1250 <1 80 s,p 10 s 11.6 2.4 19.6 <1.0 107.8 <1.0
7 256 <1 88 <1 20 s (—) 14.8 1.7 17.3 <1.0 5.9 <1.0
8 59 <1 67 <1 NTd NTd 12.0 7.0 4.9 <1.0 5.6 <1.0
9 450 <1 139 <1 40 s,p 3 s 16.8 2.5 27.2 <1.0 8.3 <1.0
One RIA unit is the amount of antibody required to induce 50% binding with the radiolabeled antigens.
b Urine samples were concentrated 50- to 100-fold.
"Anti-nuclear factors were determined by indirect immunofluorescent technique using rat liver sections. The titer was expressed as the highest
dilution which induced detectable nuclear fluorescence with homogeneous (h), speckled (s), and peripheral (p) patterns.
d NT, not tested.
Fig. 2. Gel filtration of the urine from a SLE patients with heavy
proteinuria. A concentrated urine sample was chromatographed by the
same method as described in the legend of Figure 1. The solid line
represents the IgG concentration determined by radioimmunoassay,
and the dotted line represents absorbance at 280 nm. Essentially all the
IgG activity determined by the immunological method appeared at the
position of intact JgG molecules.
was 0.25 0.15, and that of 28 normal controls (10 males and 18
females, aged 18 to 55 years) was 0.19 0.07; the difference
was not significant at a P value of 0.1. There was no significant
difference between the excretion of ssDNA by SLE patients
with heavy proteinuria exceeding 300 mg/dl (0.15 0.06, N = 4)
and by those without (0.26 0.16, N = 24).
Digestion of urine samples by DNase for the detection of
DNA-anti-DNA complexes. To see if DNA in the urine of SLE
patients had been complexed with anti-DNA and would give
negative results in anti-ssDNA assays even though it had been
existent, the following experiment was carried out (Table 3).
Serum and concentrated urine samples from the nine patients
were tested for binding with '251-ssDNA before and after
DNase digestion. Serum samples were diluted so as to maintain
Concentrated urine, pi, or ssDNA, ng, added
Fig. 3. Inhibition curves of standard ssDNA and concentrated urine of a
SLE patient. The open triangles and the dotted line represent the
percent inhibition of the binding of 4 ng of '251-ssDNA and 0.005 ,td of
rabbit anti-ssSNA antiserum by serial dilution of unlabeled ssDNA.
Open circles and the solid line represent the inhibition curve of
concentrated urine sample from a SLE patient.
the same IgG concentration as the corresponding urine samples
to facilitate the comparison. At the concentration of IgG tested,
anti-DNA activity was still detectable in seven serum concen-
trations, but it was not detectable in any of the nine urine
samples. In some serum concentrations, anti-ssDNA activity
increased after DNase digestion, indicating the presence of
immune complexes involving ssDNA. In all the urine samples
tested, however, anti-ssDNA activity was not generated even
after DNase digestion, thereby indicating the absence of anti-
DNA complexing with naturally occurring DNA in the urine.
These results were consistent with the notion that anti-DNA
had not been excreted into the urine of the patients with heavy
proteinuria.
To evaluate the validity of DNase digestion, several serum
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Table 3. Effect of DNase digestion on anti-ssDNA activity of serum
and urine of SLE patients'
Patieflt
Serum'
RIA U/mi'
U rifle
RIA U/mi
Digested Digested
no. Undigested with DNase Undigested with DNase
1 16 45 <10 <10
2 125 178 <10 <10
3 53 63 <10 <10
4 <10 <10 <10 <10
5 21 23 <10 <10
6 71 82 <10 <10
7 <10 <10 <10 <10
8 34 37 <10 <10
9 250 222 <10 <10
a Forty-five milliliters of serum or urine sample were incubated with 5
g of DNase for 1 hr at 37° C and an additional 18 hr at 4° C and 2 hr at
24°C. Then 5 1.d of 0.5 M EDTA and 395 1 of borate buffer were added
to stop the digestion. A 200-pd portion was tested for the binding with 2
ng ssDNA by radioimmunoassay. In the undigested control samples,
EDTA was added prior to the treatment with DNase.
b Serum samples were diluted to maintain the same IgG concentra-
tion as in the corresponding urine samples.
'One RIA unit is the amount of antibody required to induce 50%
binding with the radiolabeled antigens.
samples from SLE patients containing anti-ssDNA were incu-
bated with an excess amount of ssDNA for 1 hr at 37°C and an
additional 18 hr at 4°C. After the digestion of the mixture with
DNase, anti-DNA activity was determined and compared with
that of the untreated serum. Anti-DNA activity of 70% or more
of the original serum was invariably recovered after digesting
ssDNA-anti-ssDNA complexes.
Discussion
Hecht et al [81 noted a rapid decrease in DNA binding activity
of the serum from SLE patients with massive proteinuria. We
also observed that the serum levels of anti-DNA in some SLE
patients decreased after they developed nephrotic syndrome
(unpublished observations). To evaluate the contribution of
urinary loss of anti-DNA to the lowered level of circulating anti-
DNA in nephrotic patients, we determined anti-DNA activity
and IgG concentration in paired serum and urine samples of
nine patients with heavy proteinuria. In all of these patients,
anti-DNA activity was barely detectable in the urine which had
been concentrated 50- to 100-fold, and accordingly, the ratio of
anti-DNA activity (RIA units/mi) to IgG concentration (mg/ml)
was much lower for the urine than for the corresponding serum.
This led us to suspect a specific deprivation of anti-DNA from
IgG in the process of urine formation. The standardization of
anti-DNA activity to IgG was based on the finding that IgG
substantiated essentially all of the anti-DNA activity in the
serum concentrations of SLE patients on the present series, in
accordance with the reports of others [14—16].
The failure to detect anti-DNA in the urine was not due to
substances which inhibited antigen-antibody reactions, since
both IgG and ANF were detectable in the urine by immunologi-
cal methods without any difficulties. When urine samples were
fractionated by gel filtration, essentially all the antigenic activi-
ty of IgG appeared at the position of intact IgG molecules.
Therefore, the low ratio of anti-DNA/IgG in the urine of SLE
patients was not due to the overestimation of IgG by detecting
fragments of IgG without antibody activity.
An incidental finding was the presence of ssDNA in the urine
of SLE patients, as well as in that of normal individuals,
although its origin was not identified in this study. ssDNA
would be too large to be filtered across the glomerular basement
membrane (GBM) into the urine. A contamination from cellular
elements in the urine was avoided, as far as possible, by the
centrifugation immediately after voiding. Therefore, ssDNA
would have been added to the urine while it passed through the
urinary tract; it might have been released from tubular cells as a
product of their metabolism. dsDNA molecules might have
been present in the urine also, but it was not determined owing
to the difficulty in obtaining anti-dsDNA of the defined
specificity.
The presence of ssDNA in the urine of SLE patients left us
with the possibility that anti-ssDNA might have been excreted
into the urine but escaped the detection due to their binding
with ssDNA contained in the urine. This was not the case,
however, because no anti-DNA activity was generated in the
urine even after it had been digested with DNase, a procedure
capable of liberating anti-DNA antibodies from immune com-
plexes involving DNA antigens [11]. Furthermore, Sarai et al
[171 reported that anti-DNA complexed with DNA antigens was
detected more easily when it had been incubated with excess
antigens prior to the digestion with DNase. Their view was
substantiated by our finding that sera containing anti-ssDNA,
when incubated with an excess amount of ssDNA and then
digested with DNase, recovered at least 70% of the original
anti-ssDNA activity. These lines of evidence precluded the
presence of anti-ssDNA antibodies in the urine of these pa-
tients; anti-DNA in urine samples, even if it had been com-
plexed with DNA antigens, would not have escaped the detec-
tion. Accordingly, we had to postulate the entrapment of anti-
DNA antibodies by the kidney during their passage through
renal glomeruli. Since the other anti-nuclear antibodies, in
homogenous and speckled patterns, were detectable by immu-
nofluorescent method in the concentrated urine of the patients,
anti-DNA antibodies would have been specifically taken up by
the kidneys of SLE patients.
Among many organs involved in SLE, the kidney is affected
most frequently. It is known to be involved even in the very
early stage of the disease [18], and DNA-anti-DNA complexes
have been implicated in the pathogenesis of lupus nephritis [19].
There have been several reports which documented anti-DNA
antibodies in the affected kidney of SLE patients; anti-DNA
antibodies were demonstrated in a high concentration in acid
buffer or DNase eluate of nephritic kidneys [20—23]. The eluted
anti-DNA antibodies appeared to have been complexed with
DNA antigens deposited in the kidney; the antigens were
stained by fluoresceinated anti-DNA reagents after the elution
of anti-DNA [23, 24]. It is not clear, however, how DNA-anti-
DNA complexes were localized in the kidney. Some investiga-
tors claim that circulating DNA-anti-DNA complexes may be
deposited in renal glomeruli during their passage through the
kidney [11, 25, 26]. However, circulating immune complexes
are not always demonstrable in the serum of patients with lupus
nephritis even with the advent of various methods.
Izui, Lambert, and Miescher [27] proposed a hypothesis that
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DNA-anti-DNA complexes would be formed in situ in renal
glomeruli, on the basis of their finding that DNA molecules
showed an affinity to GBM. DNA molecules, once attached to
GBM, would be able to bind with circulating anti-DNA. Our
data appear to support their hypothesis. Indeed, during its
filtration through GBM, anti-DNA antibodies in the serum of
our patients may have been entrapped by renal glomeruli to
which DNA antigens had been already fixed by non-immuno-
logical processes, so that we could not find anti-DNA activity in
their urine.
The entrapment of anti-DNA antibodies by renal glomeruli
reported herein by no means rules out the contribution of
circulating immune complexes to the lowered level of anti-DNA
in the serum of nephritic patients. When DNA antigens are
released into the circulation of SLE patients by unidentified
mechanism, they would bind with anti-DNA, form immune
complexes, and then be cleared away by the reticuloendothelial
system. A part of such immune complexes would deposit in
renal glomeruli. Some antigenic sites of DNA might still be
available on the surface of DNA-anti-DNA complexes deposit-
ed in the kidney, which, in turn, could bind with circulating
anti-DNA antibodies to form complexes in situ. Indeed, these
processes operating in concert would be responsible for the
lowered anti-DNA levels in the serum concentrations of SLE
patients with renal involvement.
Reprint requests to Dr. A. Yamada, Department of Medicine,
Division of Rheumatology and Immunology, The University of North
Carolina at Chapel Hill, 932 Faculty Laboratory Office Building 231H,
Chapel Hill, North Carolina 27514, USA
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